Britain’s National Health Service should cover the multiple sclerosis therapy Extavia, the National Institute for Health and Care Excellence (NICE) has recommended. The health service usually follows the institute’s ... Read more
Novartis’ Gilenya and interferon beta-1b-based therapies stop multiple sclerosis patients’ cognitive decline, a Phase 4 clinical trial shows.
Gilenya also reduces patients’ relapses and the number of ... Read more
Most multiple sclerosis patients who try Bayer’s BETACONNECT auto-injector stick with their treatment, a study reports.
The electronic product may overcome the problem of many patients failing to stick ... Read more
A study published in the BMC Neurology journal emphasized that clear and regular communication between physicians and patients with multiple sclerosis (MS) is essential for patient satisfaction with ... Read more
Relapsing multiple sclerosis patients who begin taking Betaferon/Betaseron (interferon beta-1b) immediately after the first MS-related neurologic symptoms appear may realize slower disease progression than those who delay treatment, ... Read more
A long-term study underscores the potential benefits, especially in terms of relapses, of multiple sclerosis (MS) patients beginning treatment as soon as possible after symptoms appear — even before the disease ... Read more
Back in February, a study showed the variability of immune responses in different people with multiple sclerosis (MS) and suggested this heterogeneity affected responses to the commonly prescribed MS medication ... Read more
Global pharma Bayer Healthcare aims to improve human health by diagnosing, preventing, and treating a variety of diseases. The company currently provides products for general medicine, hematology, neurology, oncology, ... Read more
Pin It on Pinterest